UNRESECTABLE BREAST CARCINOMA
Clinical trials for UNRESECTABLE BREAST CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new UNRESECTABLE BREAST CARCINOMA trials appear
Sign up with your email to follow new studies for UNRESECTABLE BREAST CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New hope for hard-to-treat breast cancer: immune-boosting combo trial underway
Disease control OngoingThis study tests whether combining the immunotherapy drug avelumab with other medications can help people with advanced triple-negative breast cancer. About 145 adults with stage IV or inoperable breast cancer will receive one of several drug combinations. The goal is to see if t…
Matched conditions: UNRESECTABLE BREAST CARCINOMA
Phase: PHASE2 • Sponsor: Laura Huppert, MD, BA • Aim: Disease control
Last updated May 26, 2026 03:15 UTC
-
New combo attack on Hard-to-Treat cancers shows early promise
Disease control OngoingThis early-phase trial tests a combination of two drugs—trastuzumab deruxtecan (a targeted chemotherapy) and ceralasertib (which blocks a DNA repair enzyme)—in people with advanced solid tumors that have a HER2 mutation. The goal is to find the safest dose and see if the combo wo…
Matched conditions: UNRESECTABLE BREAST CARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 03:13 UTC
-
New combo shows promise against tough breast cancer
Disease control OngoingThis study tests a new drug called onvansertib combined with standard chemotherapy (paclitaxel) in people with triple-negative breast cancer that has spread to other parts of the body. About 50 adults with advanced disease are participating to see if the combination is safe and c…
Matched conditions: UNRESECTABLE BREAST CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Antonio Giordano, MD • Aim: Disease control
Last updated May 26, 2026 03:11 UTC
-
New drug combo targets BRCA cancers in early trial
Disease control OngoingThis early-phase trial tests a combination of two drugs—niraparib (a PARP inhibitor) and dostarlimab (an immunotherapy)—in people with BRCA-mutated breast, pancreas, or ovarian cancers that have spread or cannot be surgically removed. The goal is to see if the combo can shrink tu…
Matched conditions: UNRESECTABLE BREAST CARCINOMA
Phase: PHASE1 • Sponsor: University of Washington • Aim: Disease control
Last updated May 18, 2026 12:13 UTC
-
New drug targets Hard-to-Treat HER2 cancers in early trial
Disease control OngoingThis early-stage study tests an experimental drug called BL-M17D1 in 120 adults with advanced solid tumors that have a specific protein (HER2) or a HER2 gene change. The main goals are to check the drug's safety, find the right dose, and see if it shrinks tumors. Participants mus…
Matched conditions: UNRESECTABLE BREAST CARCINOMA
Phase: PHASE1 • Sponsor: SystImmune Inc. • Aim: Disease control
Last updated May 18, 2026 12:07 UTC
-
New combo therapy aims to turn tumors against themselves in advanced cancer patients
Disease control OngoingThis early-phase study tests whether a mix of drugs and targeted radiation can help the immune system recognize and attack hard-to-treat solid tumors. About 14 adults with advanced melanoma, breast cancer, or other solid cancers that cannot be surgically removed will receive inje…
Matched conditions: UNRESECTABLE BREAST CARCINOMA
Phase: PHASE1 • Sponsor: University of Southern California • Aim: Disease control
Last updated May 11, 2026 20:38 UTC